We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+48.38%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.77B
AUM Growth
+$389M
Cap. Flow
-$37.2M
Cap. Flow %
-2.11%
Top 10 Hldgs %
60.65%
Holding
62
New
13
Increased
10
Reduced
5
Closed
11

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$53M
2
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$51.2M
3
SAGE
Sage Therapeutics
SAGE
+$43.1M
4
ANAB icon
AnaptysBio
ANAB
+$30.7M
5
IMMU
Immunomedics Inc
IMMU
+$26.5M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$160M
2
AMRN
Amarin Corp
AMRN
+$53.1M
3
PTCT icon
PTC Therapeutics
PTCT
+$33.8M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$32.8M
5
SLDB icon
Solid Biosciences
SLDB
+$21.1M

Sector Composition

Rank Sector Weight
1 Healthcare 81.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
26
DELISTED
Global Blood Therapeutics, Inc.
GBT
$19.9M 1.12%
250,000
– –
ACHN
27
DELISTED
Achillion Pharmaceuticals
ACHN
$18.2M 1.03%
3,000,000
+1,000,000
+50% +$5.79M
PRVL
28
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$17.8M 1.01%
1,123,105
– –
MIST icon
29
Milestone Pharmaceuticals
MIST
$138M
$17.6M 1%
1,102,194
– –
RCUS icon
30
Arcus Biosciences
RCUS
$3.55B
$16.9M 0.96%
1,672,233
+1,372,233
+457% +$11.5M
VXX icon
31
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
$154M
$15.1M 0.86%
+15,625
New +$18.9M
ARVN icon
32
Arvinas
ARVN
$518M
$15M 0.85%
+366,000
New +$10.7M
BLU
33
DELISTED
BELLUS Health Inc.
BLU
$13.5M 0.76%
1,775,000
– –
NGNE icon
34
Neurogene
NGNE
$656M
$12.4M 0.7%
+50,463
New +$5.03M
RLMD icon
35
Relmada Therapeutics
RLMD
$557M
$11.7M 0.66%
+300,000
New +$9.12M
KURA icon
36
Kura Oncology
KURA
$800M
$11.6M 0.66%
844,789
– –
LXRX icon
37
Lexicon Pharmaceuticals
LXRX
$1.03B
$11.5M 0.65%
2,775,000
+275,000
+11% +$1.06M
AKRO
38
DELISTED
Akero Therapeutics
AKRO
$10.7M 0.61%
482,495
– –
MRNS
39
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$10.4M 0.59%
+1,200,000
New +$6.73M
MDCO
40
CALL
DELISTED
Medicines Co
MDCO
$8.49M 0.48%
+100,000
New +$6.67M
RNAC icon
41
Cartesian Therapeutics
RNAC
$229M
$7.82M 0.44%
+109,469
New +$5.28M
MIRM icon
42
Mirum Pharmaceuticals
MIRM
$6.46B
$7.77M 0.44%
+317,000
New +$3.38M
LITS
43
Lite Strategy Inc
LITS
$32.8M
$7.22M 0.41%
145,655
– –
IDYA icon
44
IDEAYA Biosciences
IDYA
$3.42B
$5.73M 0.32%
764,252
– –
SLDB icon
45
Solid Biosciences
SLDB
$794M
$4.59M 0.26%
68,791
-191,000
-74% -$21.1M
CBAY
46
DELISTED
Cymabay Therapeutics
CBAY
$3.92M 0.22%
2,000,000
+750,000
+60% +$2.82M
KALV
47
DELISTED
KalVista Pharmaceuticals
KALV
$3.56M 0.2%
200,000
– –
KNSA icon
48
Kiniksa Pharmaceuticals
KNSA
$5.8B
$3.21M 0.18%
290,577
– –
LJPC
49
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.05M 0.17%
775,000
– –
SNDX icon
50
Syndax Pharmaceuticals
SNDX
$1.69B
$2.19M 0.12%
250,000
-150,000
-38% -$1.1M
1
2
3

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2019 Portfolio in Review

As of Q4 2019, Boxer Capital held 62 positions worth $1.77B, up 28% from $1.38B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Boxer Capital's Q4 2019 filing shows 13 new, 10 increased, 5 reduced and 11 closed positions. Its largest new stake was Seagen Inc. Common Stock: 500,000 shares worth $57.1M. The largest sale was Spark Therapeutics, Inc. Common Stock, an estimated $160M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 78% a quarter earlier.

  • Boxer Capital's largest Q4 2019 buy was Seagen Inc. Common Stock: 500,000 shares worth $57.1M.
  • Boxer Capital added most to Immunomedics Inc in Q4 2019, an estimated $26.5M increase.
  • Boxer Capital's biggest Q4 2019 reduction was Sarepta Therapeutics, cutting an estimated $32.8M.
  • Boxer Capital fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $160M.
  • Boxer Capital's ten largest holdings make up 61% of its $1.77B portfolio in Q4 2019.
  • Boxer Capital opened 13 new positions and closed 11 in Q4 2019.
  • Boxer Capital's portfolio value rose 28% quarter-over-quarter to $1.77B.

Based on Boxer Capital's 13F filing for Q4 2019, filed 14 Feb 2020.